Abstract: A diffractometric sensor (1), comprises:—a substrate (3);—two interdigitated affinity gratings (2), a first affinity grating (20) comprising first unit cells (200) with affinity elements (201) and a second affinity grating (21) comprising second unit cells (210) with affinity elements (211), wherein the first unit cells (200) and second unit cells (210) are configured and arranged such that coherent light of a predetermined wavelength generated at a predetermined beam generation location (40) and diffracted by target molecules (204, 214)) bound to the affinity elements (201, 211) constructively interferes at a predetermined detection location (50) with an inverse phase, and wherein the first and second affinity gratings (20, 21) are balanced to generate a bias signal at the predetermined detection location (50) that corresponds to a difference (Am) in the scattering mass of the first and second affinity gratings (20, 21) which is in the range of 0.001 pg/mm2 to 30000 pg/mm2.

Abstract: Disclosed herein is an artificial transmembrane protein for use in a biomolecular detection device for detecting intracellular or intravesicular biomolecular interactions, the artificial transmembrane protein having an extracellular or extravesicular binder structure, a hydrophobic transmembrane domain, and an intracellular or intravesicular domain with an intracellular or intravesicular receptor structure, wherein the receptor structure is configured to interact with an intracellular or intravesicular component of the biomolecular interaction to be detected and wherein the extracellular or extravesicular binder structure is configured to bind to membrane recognition elements arranged along a plurality of predetermined lines of the biomolecular detection device.

Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.

Abstract: A system for shortening incubation times on immunoassays employs energy that is applied to the assays. Energy is applied in careful gradations so that chemical bonds are not broken. If polyclonal antibodies, as opposed to monoclonal antibodies, are worked with, then because the bonds are stronger, cooling is employed in combination with the extra energy delivered.

Abstract: Electrophoretically enhanced methods are disclosed for carrying out binding and other reactions using pulsating and polarity reversing electric fields. The methods are exemplified by E3 ELISAs using free flow electrophoresis in multiwell plates and E3 Westerns using saturated matrices. The E3 methods are much faster than conventional methods and provide superior results. Reagents, buffers, devices and power supplied for carrying out E3 methods are disclosed.

Abstract: A microarray device for the analysis of biological samples is provided. The device includes a liquid permeable layer having a plurality of microregions, each including a plurality of probe-labeled microbeads embedded in the liquid permeable layer. The microbeads in a given microregion include a plurality of the same target probes on their surfaces. The target probes are capable of specifically binding to one or more particular target molecules (e.g., nucleic acid, polypeptide, small molecule antigen). The device typically has the capability of inducing a sample solution to move through the liquid permeable layer under the influence of an applied voltage. Kits which include the device and methods of simultaneously detecting a plurality of different target molecules in a sample solution are also provided.